BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 24909984)

  • 1. Weight-neutral effect of once-daily insulin detemir in Chinese type 2 diabetes patients: subgroup analysis of the SOLVE study.
    Pan C; Han P; Ji L; Ji Q; Lu J; Lin J; Liu J; Su B; Shi J; Wang P
    J Diabetes; 2015 Mar; 7(2):222-30. PubMed ID: 24909984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin detemir improves glycaemic control without weight gain in insulin-naïve patients with type 2 diabetes: subgroup analysis from the PREDICTIVE study.
    Dornhorst A; Lüddeke HJ; Sreenan S; Kozlovski P; Hansen JB; Looij BJ; Meneghini L;
    Int J Clin Pract; 2008 Apr; 62(4):659-65. PubMed ID: 18324957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and effectiveness of insulin detemir in combination with oral antidiabetic agents in an outpatient specialist setting: results of the Italian SOLVE™ observational study.
    Caputo S; Maran A; Mannino D; Morano S; Lastoria G; Nicoziani P
    Minerva Endocrinol; 2015 Dec; 40(4):249-58. PubMed ID: 26551483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The safety and effectiveness of once daily detemir in patients with type 2 diabetes previously failing oral agents: the Chinese cohort from SOLVE(TM) observational study].
    Pan CY; Ji LN; Lu JM; Yang WY; Zhou ZG; Zou DJ; Ji QH; Han P; Liu J; Li Q; Su BL; Li YB; Gao ZN; Wang PH; Yin SN; Dong YH; Yang T; Sun K; Li H; Hong X; Lin J; Shi JM; Yang XJ; Fang H; Yan XD;
    Zhonghua Nei Ke Za Zhi; 2013 Jan; 52(1):11-5. PubMed ID: 23710808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohort.
    Dornhorst A; Lüddeke HJ; Sreenan S; Koenen C; Hansen JB; Tsur A; Landstedt-Hallin L
    Int J Clin Pract; 2007 Mar; 61(3):523-8. PubMed ID: 17313628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of once-daily insulin detemir on oral antidiabetic drug (OAD) use in patients with type 2 diabetes.
    Vora J; Caputo S; Damci T; Orozco-Beltran D; Pan C; Svendsen AL; Sølje KS; Khunti K;
    J Clin Pharm Ther; 2014 Apr; 39(2):136-43. PubMed ID: 24329524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial.
    Fajardo Montañana C; Hernández Herrero C; Rivas Fernández M
    Diabet Med; 2008 Aug; 25(8):916-23. PubMed ID: 18959604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once-daily insulin detemir in a cohort of insulin-naïve patients with type 2 diabetes: a sub-analysis from the PREDICTIVE study.
    Meneghini LF; Dornhorst A; Sreenan S;
    Curr Med Res Opin; 2009 Apr; 25(4):1029-35. PubMed ID: 19281426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Once daily insulin detemir in patients with type 2 diabetes: results of German centers in a 6-month international observational study (SOLVE)].
    Liebl A; Wilhelm B; Kaiser M
    MMW Fortschr Med; 2012 Dec; 154 Suppl 4():102-9. PubMed ID: 23326928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes--results of the randomized, controlled PREDICTIVE 303 study.
    Meneghini L; Koenen C; Weng W; Selam JL
    Diabetes Obes Metab; 2007 Nov; 9(6):902-13. PubMed ID: 17924873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of once-daily insulin detemir in patients with type 2 diabetes treated with oral hypoglycemic agents in routine clinical practice.
    Ross S; Dzida G; Ji Q; Kaiser M; Ligthelm R; Meneghini L; Nazeri A; Orozco-Beltran D; Pan C; Svendsen AL;
    J Diabetes; 2014 May; 6(3):243-50. PubMed ID: 24103141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved glycaemic control with no weight gain: a 26-week, open label, non-randomised, non-interventional observational study on type 2 diabetes subjects using insulin detemir.
    Tripathi S; Chandalia HB; Rao PV; Badgandi M; Patni R; Subbanna PK; Shetty R; Kumar H
    J Indian Med Assoc; 2011 Apr; 109(4):275-8. PubMed ID: 22187803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
    Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G
    Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain: 52-week data from the PREDICTIVE study in a cohort of French patients with type 1 or type 2 diabetes.
    Marre M; Pinget M; Gin H; Thivolet C; Hanaire H; Robert JJ; Fontaine P
    Diabetes Metab; 2009 Dec; 35(6):469-75. PubMed ID: 19914118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [RESOLUTE Study in the Czech Republic: insulin glargine improves the compensation of type 2 diabetes in patients with unsatisfactory results of therapy with a combination of insulin detemir and oral antidiabetics. Results of the nonintervention RESOLUTE Project in the Czech Republic].
    Kvapil M
    Vnitr Lek; 2013 Sep; 59(9):800-6. PubMed ID: 24073952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: Chinese PRESENT study.
    Gao Y; Guo XH; Vaz JA;
    Diabetes Obes Metab; 2009 Jan; 11(1):33-40. PubMed ID: 18494806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are insulin analogues detemir or glulisine used preferentially in overweight/obese subjects? A German multicentre analysis of 38560 type 2 diabetic patients from the DPV registry.
    Bohn B; Scheuing N; Jehle PM; Laubner K; Born B; Merger S; Hummel M; Krakow D; Voll A; Zimmermann A; Zimny S; Holl RW;
    Exp Clin Endocrinol Diabetes; 2014 Nov; 122(10):602-7. PubMed ID: 25054308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes.
    Haak T; Tiengo A; Draeger E; Suntum M; Waldhäusl W
    Diabetes Obes Metab; 2005 Jan; 7(1):56-64. PubMed ID: 15642076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Weight change upon once-daily initiation of insulin detemir with or without dietary intervention in overweight or obese insulin-naïve individuals with type 2 diabetes: results from the DIET trial.
    Niswender K; Piletic M; Andersen H; Conradsen Hiort L; Hollander P
    Diabetes Obes Metab; 2014 Feb; 16(2):186-92. PubMed ID: 24112375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved glycemic control with weight loss and a low risk of hypoglycemia with insulin detemir: insights from the Italian cohort of the PREDICTIVE study after 6-month observation in type 2 diabetic subjects.
    Perriello G; Caputo S; De Pergola G; Di Carlo A; Grassi G; Lapolla A; Pata P; Solerte SB; Zaccardi F
    Expert Opin Pharmacother; 2011 Nov; 12(16):2449-55. PubMed ID: 21988213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.